Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Icecure Medical Ltd Ord (ICCM)

Icecure Medical Ltd Ord (ICCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,227
  • Shares Outstanding, K 68,699
  • Annual Sales, $ 3,290 K
  • Annual Income, $ -15,320 K
  • EBIT $ -4 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.29
  • Price/Sales 14.42
  • Price/Cash Flow N/A
  • Price/Book 5.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.26
  • Most Recent Earnings $-0.06 on 11/19/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Services

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5800 +22.47%
on 12/31/25
0.7200 -1.35%
on 12/17/25
+0.0154 (+2.22%)
since 12/09/25
3-Month
0.5800 +22.47%
on 12/31/25
0.9820 -27.67%
on 10/10/25
-0.2540 (-26.34%)
since 10/09/25
52-Week
0.5800 +22.47%
on 12/31/25
1.6600 -57.21%
on 02/19/25
-0.5797 (-44.94%)
since 01/08/25

Most Recent Stories

More News
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States

ICCM : 0.7103 (+1.18%)
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense®

ICCM : 0.7103 (+1.18%)
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Cryogenic flow control enhances the efficacy and precision of cryoablation procedures

ICCM : 0.7103 (+1.18%)
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast cancer

ICCM : 0.7103 (+1.18%)
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

This latest approval further broadens global access to ProSense® and supports IceCure's commercial momentum following the U.S. Food and Drug Administration's ("FDA") recent marketing authorization of...

ICCM : 0.7103 (+1.18%)
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

CAESAREA, Israel , Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an...

ICCM : 0.7103 (+1.18%)
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

CAESAREA, Israel , Nov. 12, 2025 /PRNewswire/ --  IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...

ICCM : 0.7103 (+1.18%)
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense®

ICCM : 0.7103 (+1.18%)
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT alone 

ICCM : 0.7103 (+1.18%)
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

FDA's marketing authorization for ProSense® for low-risk breast cancer received following the TME Fall Summit—Marketing authorization expected to further drive commercial traction based on the high...

ICCM : 0.7103 (+1.18%)

Business Summary

IceCure Medical Ltd. develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. IceCure Medical Ltd. is based in CAESAREA, Israel.

See More

Key Turning Points

3rd Resistance Point 0.7382
2nd Resistance Point 0.7290
1st Resistance Point 0.7196
Last Price 0.7103
1st Support Level 0.7010
2nd Support Level 0.6918
3rd Support Level 0.6824

See More

52-Week High 1.6600
Fibonacci 61.8% 1.2474
Fibonacci 50% 1.1200
Fibonacci 38.2% 0.9926
Last Price 0.7103
52-Week Low 0.5800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar